These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20930642)

  • 1. Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
    Frenette CT; Frederick RT; Gish RG
    J Clin Gastroenterol; 2011 Sep; 45(8):733-7. PubMed ID: 20930642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S; McTigue M; Finn RS; Busuttil RW
    Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
    Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
    Inuzuka T; Nishikawa H; Sekikawa A; Takeda H; Henmi S; Sakamoto A; Saito S; Kita R; Kimura T; Osaki Y; Kudo M
    Oncology; 2011; 81 Suppl 1():152-7. PubMed ID: 22212950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
    Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
    Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
    Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
    Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
    Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
    Song T; Zhang W; Wu Q; Kong D; Ma W
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
    Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
    Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
    Curtit E; Thiery-Vuillemin A; Nguyen T; Heyd B; Pivot X; Di Martino V; Borg C
    J Clin Oncol; 2011 Apr; 29(12):e330-2. PubMed ID: 21263091
    [No Abstract]   [Full Text] [Related]  

  • 16. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
    Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib in advanced hepatocellular carcinoma.
    Llovet JM; Ricci S; Mazzaferro V; Hilgard P; Gane E; Blanc JF; de Oliveira AC; Santoro A; Raoul JL; Forner A; Schwartz M; Porta C; Zeuzem S; Bolondi L; Greten TF; Galle PR; Seitz JF; Borbath I; Häussinger D; Giannaris T; Shan M; Moscovici M; Voliotis D; Bruix J;
    N Engl J Med; 2008 Jul; 359(4):378-90. PubMed ID: 18650514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
    Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P
    Digestion; 2011; 83(4):275-82. PubMed ID: 21282952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports.
    Takahara T; Nitta H; Hasegawa Y; Itou N; Takahashi M; Wakabayashi G
    Transplant Proc; 2011 Sep; 43(7):2800-5. PubMed ID: 21911167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Rimassa L; Santoro A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.